Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Toros University
Pfizer
Eli Lilly and Company
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
Eastern Cooperative Oncology Group
Colorado State University
Orano Med LLC
Wake Forest University Health Sciences
M.D. Anderson Cancer Center
Zagazig University
Gustave Roussy, Cancer Campus, Grand Paris
Kaiser Permanente
University of Pennsylvania
Duke University
MBrace Therapeutics
Ulsan University Hospital
New Phase Ltd.
University of Colorado, Denver
Unity Health Toronto
City of Hope Medical Center
Eli Lilly and Company
Novartis
Var2 Pharmaceuticals
Universidad Complutense de Madrid
Dokuz Eylul University
University of Salamanca
AC Camargo Cancer Center
City of Hope Medical Center
NantCell, Inc.
Vejle Hospital
City of Hope Medical Center
AstraZeneca
Tempus AI
UNC Lineberger Comprehensive Cancer Center
Virginia Commonwealth University
University of Calgary
New Mexico Cancer Research Alliance
Arab American University (Palestine)
A2 Biotherapeutics Inc.
Centre Hospitalier de Valence
Eli Lilly and Company
GONGCHU Biotechnology Co., Ltd
Palleon Pharmaceuticals, Inc.
Sensei Biotherapeutics, Inc.
Jonsson Comprehensive Cancer Center
Centre for Research and Technology Hellas